Collaboration agreement within IUI, Intra-Uterine Insemination

Collaboration agreement within IUI, Intra-Uterine Insemination

Vitrolife is entering into a collaboration agreement with ParentPlus
LLC, with the aim of developing new products for IUI (Intra-Uterine
Insemination, artificial insemination).

In many countries IUI treatment is a requirement before IVF (In Vitro
Fertilization) treatment can begin. It is estimated that there is a
market for between 4-6 million treatments a year, with a market value of
SEK 1-2 billion. IUI, “artificial insemination”, is a process where the
sperm are prepared by separating them from the seminal fluid and then
injecting them so that a high concentration of active and mobile sperm
are introduced directly through the cervix into the uterus and the
fallopian tubes, where fertilization of the egg takes place. The method
is simple and cost-effective and more or less doubles the chances of
getting pregnant compared with intercourse during the estimated
ovulation period, but it has limitations concerning which groups the
treatment works for.

“The reason that we are now choosing to try to develop products for this
part of the infertility market, which Vitrolife has previously not
actively processed, is that we see opportunities to be able to increase
the value of IUI within assisted fertilization through more effective
treatment. The very number of treatments in itself constitutes a great
business opportunity,” says Tony Winslöf, Director of Business
Development at Vitrolife.

“If we can develop IUI treatment in the same way as we have contributed
to development within IVF, Vitrolife will have a unique position with
regard to effect and quality within fertility treatment,” says Magnus
Nilsson, CEO at Vitrolife.

Gothenburg, November 11, 2011

VITROLIFE AB (publ)

Magnus Nilsson

CEO

Queries should be addressed to:

Magnus Nilsson, CEO, phone +46 31 721 80 61

Mikael Engblom, CFO, phone +46 31 721 80 14